Antihypertensive treatments in patients affected by aortic valve stenosis

Research output: Contribution to journalReview articlepeer-review


Systemic hypertension and aortic valve stenosis (AVS) are both age-related diseases. Severe aortic stenosis affects ≈2% to 5% of adults age > 65 years. Systemic hypertension is a frequent comorbidity in patients with AVS and is coexistent for a longer period of time before AVS is treated. Essential systemic hypertension, per se, plays an important role in the creation of lesions on the aortic side of the valve, the region of higher exposure to tension stress. The subsequent endothelial defect represents the principal site of inflammatory process and oxidative stress, leading to aortic sclerosis and calcification. In this review, we want to describe the pharmacological features of the common antihypertensive drugs, analysing the recent literature, in order to achieve useful and updated information about the best treatment of systemic hypertension in patients with concomitant severe aortic stenosis.

Original languageEnglish
Pages (from-to)1188-1194
Number of pages7
JournalCurrent Pharmaceutical Design
Issue number8
Publication statusPublished - Mar 1 2017


  • ACEi/ARB
  • Alpa- beta-blockers
  • Antihypertensive drugs
  • Aortic valve stenosis
  • Calcium channel blockers
  • Diuretics
  • Hypertension
  • Vasodilators

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery


Dive into the research topics of 'Antihypertensive treatments in patients affected by aortic valve stenosis'. Together they form a unique fingerprint.

Cite this